Basal cell adenocarcinoma of the supraglottic larynx: treatment of recurrent disease with tamoxifen | Zendy

Christopher H. Bailey | Zendy; Patrick J. Donovan | Zendy; Glen J. Weiss | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Basal cell adenocarcinoma of the supraglottic larynx: treatment of recurrent disease with tamoxifen

Author(s) -

Christopher H. Bailey,

Patrick J. Donovan,

Glen J. Weiss

Publication year - 2011

Publication title -

rare tumors

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.285

H-Index - 15

eISSN - 2036-3613

pISSN - 2036-3605

DOI - 10.4081/rt.2011.e55

Subject(s) - medicine , adenocarcinoma , tamoxifen , larynx , pathological , radiation therapy , stage (stratigraphy) , pathology , chemotherapy , cancer , surgery , breast cancer , paleontology , biology

At the age of 83, a woman presented with an extremely rare cancer, basal cell adenocarcinoma (BCAC) of the supraglottic larynx. Pathology revealed a stage IVA tumor, pathological stage T4N0M0. She was treated with surgery and did not receive any adjuvant chemotherapy or radiation therapy. At the age of 93, during a routine examination, the patient was found to have palpable adenopathy and underwent a fine needle aspiration in June 2010. Pathology revealed similar histologic characteristics of her 2001 BCAC diagnosis, and further IHC stains revealed positive estrogen receptor staining

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research